Company: TAK
Filing Date: 2025-01-30
Form Type: 6-K
Source: 0001395064-25-000002
Chunk: 21

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-01-30
Form: 6-K
Chunk 21
---
     19.0 |      |     |        |            |                |                    |      |     19.0 |                           |
| Other operating expenses*3                                                           |     |         |                |                    |    |   -213.0 |      |     |        |            |                |                    |      |   -225.0 |                           |
| Finance income and (expenses), net                                                   |     |         |                |                    |    |   -168.0 |      |     |        |            |                |                    |      |   -178.0 |                           |
| Adjusted Free Cash Flow*1                                                            |     |         | 400.0 - 500.0  |                    |    |          |      |     |        |            | 550.0 - 650.0  |                    |      |          |                           |
| Capital expenditures (cash flow base)                                                |     |         | -380.0 - 420.0 |                    |    |          |      |     |        |            | -380.0 - 420.0 |                    |      |          |                           |
| Depreciation and amortization (excluding intangible assets associated with products) |     |         |                |                    |    |          |      |     | -215.0 |            |                |                    |      |   -218.0 |                           |
| Cash tax rate on Adjusted EBITDA (excluding divestitures)*1                          |     |         |                |                    |    |          |      |     |        | Mid teen % |                |                    |      |          | Low teen %                |

*2 Includes in-process R&D.

*3 In the Revised Forecast, there is no change in the JPY 140.0 billion restructuring expense, which is primarily related to the enterprise-wide efficiency program.

Management Guidance for the Fiscal Year Ending March 31, 2025 (FY2024)

Takeda uses change in Core Revenue, Core Operating Profit and Core EPS at Constant Exchange Rate (CER) basis as its Management Guidance. The full year management guidance for the fiscal year ending March 31, 2025 (FY2024) has been revised from the previous management guidance announced on October 31, 2024, as follows:

|                       |     | Previous Management Guidance 
 (October 31, 2024)           |     | CER % Change*1              
 Revised Management Guidance 
 (January